252 related articles for article (PubMed ID: 36834867)
21. Bombesin/oligoarginine fusion peptides for gastrin releasing peptide receptor (GRPR) targeted gene delivery.
Begum AA; Wan Y; Toth I; Moyle PM
Bioorg Med Chem; 2018 Jan; 26(2):516-526. PubMed ID: 29269254
[TBL] [Abstract][Full Text] [Related]
22. Visualization of internalization and recycling of the gastrin releasing peptide receptor-green fluorescent protein chimera expressed in epithelial cells.
Slice LW; Yee HF; Walsh JH
Recept Channels; 1998; 6(3):201-12. PubMed ID: 10100328
[TBL] [Abstract][Full Text] [Related]
23. Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes.
Smith CJ; Volkert WA; Hoffman TJ
Nucl Med Biol; 2005 Oct; 32(7):733-40. PubMed ID: 16243649
[TBL] [Abstract][Full Text] [Related]
24. In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer.
Craft JM; De Silva RA; Lears KA; Andrews R; Liang K; Achilefu S; Rogers BE
Nucl Med Biol; 2012 Jul; 39(5):609-16. PubMed ID: 22261146
[TBL] [Abstract][Full Text] [Related]
25. Identification and stabilization of a highly selective gastrin-releasing peptide receptor agonist.
Hoppenz P; Els-Heindl S; Beck-Sickinger AG
J Pept Sci; 2019 Dec; 25(12):e3224. PubMed ID: 31743956
[TBL] [Abstract][Full Text] [Related]
26. Lutetium-177 Labeled Bombesin Peptides for Radionuclide Therapy.
Reynolds TS; Bandari RP; Jiang Z; Smith CJ
Curr Radiopharm; 2016; 9(1):33-43. PubMed ID: 25771366
[TBL] [Abstract][Full Text] [Related]
27. Substitution of l-Tryptophan by
Günther T; Deiser S; Felber V; Beck R; Wester HJ
J Nucl Med; 2022 Sep; 63(9):1364-1370. PubMed ID: 35027371
[TBL] [Abstract][Full Text] [Related]
28. Evolution of bombesin conjugates for targeted PET imaging of tumors.
Zhang H; Abiraj K; Thorek DL; Waser B; Smith-Jones PM; Honer M; Reubi JC; Maecke HR
PLoS One; 2012; 7(9):e44046. PubMed ID: 23024746
[TBL] [Abstract][Full Text] [Related]
29. A comparative PET imaging study of
Ferguson S; Wuest M; Richter S; Bergman C; Dufour J; Krys D; Simone J; Jans HS; Riauka T; Wuest F
Nucl Med Biol; 2020; 90-91():74-83. PubMed ID: 33189947
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of a technetium-99m labeled bombesin homodimer for GRPR imaging in prostate cancer.
Yu Z; Carlucci G; Ananias HJ; Dierckx RA; Liu S; Helfrich W; Wang F; de Jong IJ; Elsinga PH
Amino Acids; 2013 Feb; 44(2):543-53. PubMed ID: 22833158
[TBL] [Abstract][Full Text] [Related]
31. An update of radiolabeled bombesin analogs for gastrin-releasing peptide receptor targeting.
Yu Z; Ananias HJ; Carlucci G; Hoving HD; Helfrich W; Dierckx RA; Wang F; de Jong IJ; Elsinga PH
Curr Pharm Des; 2013; 19(18):3329-41. PubMed ID: 23431995
[TBL] [Abstract][Full Text] [Related]
32. Gastrin-releasing peptide receptor agonists and antagonists for molecular imaging of breast and prostate cancer: from pre-clinical studies to translational perspectives.
Gorica J; De Feo MS; Filippi L; Frantellizzi V; Schillaci O; De Vincentis G
Expert Rev Mol Diagn; 2022 Nov; 22(11):991-996. PubMed ID: 36369779
[TBL] [Abstract][Full Text] [Related]
33. Aberrant expression of gastrin-releasing peptide and its receptor by well-differentiated colon cancers in humans.
Carroll RE; Matkowskyj KA; Chakrabarti S; McDonald TJ; Benya RV
Am J Physiol; 1999 Mar; 276(3):G655-65. PubMed ID: 10070042
[TBL] [Abstract][Full Text] [Related]
34. 18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors.
Honer M; Mu L; Stellfeld T; Graham K; Martic M; Fischer CR; Lehmann L; Schubiger PA; Ametamey SM; Dinkelborg L; Srinivasan A; Borkowski S
J Nucl Med; 2011 Feb; 52(2):270-8. PubMed ID: 21233180
[TBL] [Abstract][Full Text] [Related]
35. Gastrin-releasing peptide receptor (GRPR) as a novel biomarker and therapeutic target in prostate cancer.
Zhang H; Qi L; Cai Y; Gao X
Ann Med; 2024 Dec; 56(1):2320301. PubMed ID: 38442298
[No Abstract] [Full Text] [Related]
36. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors.
Abiraj K; Mansi R; Tamma ML; Fani M; Forrer F; Nicolas G; Cescato R; Reubi JC; Maecke HR
J Nucl Med; 2011 Dec; 52(12):1970-8. PubMed ID: 22080443
[TBL] [Abstract][Full Text] [Related]
37. Investigation of Tumor Cells and Receptor-Ligand Simulation Models for the Development of PET Imaging Probes Targeting PSMA and GRPR and a Possible Crosstalk between the Two Receptors.
Liolios C; Patsis C; Lambrinidis G; Tzortzini E; Roscher M; Bauder-Wüst U; Kolocouris A; Kopka K
Mol Pharm; 2022 Jul; 19(7):2231-2247. PubMed ID: 35467350
[TBL] [Abstract][Full Text] [Related]
38. Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer.
Liu Z; Li ZB; Cao Q; Liu S; Wang F; Chen X
J Nucl Med; 2009 Jul; 50(7):1168-77. PubMed ID: 19525469
[TBL] [Abstract][Full Text] [Related]
39. (18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer.
Liu Z; Yan Y; Liu S; Wang F; Chen X
Bioconjug Chem; 2009 May; 20(5):1016-25. PubMed ID: 20540537
[TBL] [Abstract][Full Text] [Related]
40. In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer.
Lears KA; Ferdani R; Liang K; Zheleznyak A; Andrews R; Sherman CD; Achilefu S; Anderson CJ; Rogers BE
J Nucl Med; 2011 Mar; 52(3):470-7. PubMed ID: 21321264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
